Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Cyclosporin a" patented technology

Methods of culturing mesenchymal stem cells with modulated apoptosis-specific nuclease to reduce apoptosis

The present application belongs to the field of cell biology, specifically by adding recombinant human DFF45 protein, Z-VAD-FMK, Cyclosporin A, bFGF, N-Acetylcysteine, regulating the activity and effect of apoptosis-specific nuclease, reducing the apoptosis rate of umbilical cord mesenchymal stem cells, and also can improve the proliferation effect of umbilical cord mesenchymal stem cells, the proliferation rate of umbilical cord mesenchymal stem cells is increased by 17.53%, and the apoptosis rate of umbilical cord mesenchymal stem cells by ordinary conventional culture method is reduced from 14.32% to 9.81%, effectively solving the core problem of stem cell proliferation attenuation, apoptosis rate increase in the existing culture technology, maintaining the biological activity and quality stability of stem cells in the long-term subculture process, providing reliable technical support and experimental basis for the large-scale culture, in vitro expansion and subsequent clinical transformation application of umbilical cord mesenchymal stem cells.
Owner:李春雨

Cyclosporin A chemiluminescence immunoassay reagent and preparation and detection method thereof

The present application relates to a cyclosporine A detection reagent and its preparation and detection method, specifically relates to a cyclosporine A chemiluminescence immunoassay reagent and its preparation and detection method, comprising: anti-cyclosporine A specific antibody, indicating reagent for detecting anti-cyclosporine A specific antibody-cyclosporine A combination;The above-mentioned anti-cyclosporine A specific antibody is obtained by immunizing animals with cyclosporine A immunogen.The present application has the advantages that: the cyclosporine A immunogen of the present application is specific and has high immunogenicity, and the prepared anti-cyclosporine A specific antibody is specific and has high titer;The chemiluminescence immunoassay reagent containing the above-mentioned anti-cyclosporine A specific antibody can conveniently, quickly and accurately determine the content of cyclosporine A in the sample, and multiple samples can be simultaneously determined on a fully automatic chemiluminescence immunoassay analyzer, realizing high-throughput rapid determination of cyclosporine A, high accuracy, strong specificity, and great improvement in accuracy and detection efficiency.
Owner:SUZHOU EVERMED BIOMEDICAL CO LTD